Cargando…
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma (MM). A total of 30 patients who relapsed or progressed after ≥6 months since the last dose of their previous bortezomib therapy were included in...
Autores principales: | Ahn, Jae-Sook, Jung, Sung-Hoon, Lee, Seung-Shin, Ahn, Seo-Yeon, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Kim, Hyeoung-Joon, Lee, Je-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233662/ https://www.ncbi.nlm.nih.gov/pubmed/25530955 http://dx.doi.org/10.1155/2014/145843 |
Ejemplares similares
-
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016) -
Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013) -
Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015) -
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015) -
A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
por: Bae, Soo-Young, et al.
Publicado: (2011)